Literature DB >> 29635535

Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.

Rosanna Coppo1, Licia Peruzzi2, Elisa Loiacono1, Massimilano Bergallo3, Alexandra Krutova4, Maria Luisa Russo1, Enrico Cocchi2, Alessandro Amore2, Sigrid Lundberg5, Dita Maixnerova6, Vladimir Tesar6, Agnieszka Perkowska-Ptasińska7, Magdalena Durlik7, Dimitris Goumenos8, Miltiadis Gerolymos8, Kresimir Galesic9, Luka Toric9, Aikaterini Papagianni10, Maria Stangou10, Malgorzata Mizerska-Wasia Membek11, Loreto Gesualdo12, Eustacchio Montemurno12, Luisa Benozzi13, Stefano Cusinato13, Tomasz Hryszko14, Marian Klinger15, Dorota Kamińska15, Magdalena Krajewska15.   

Abstract

BACKGROUND: Complement is thought to play a role in immunoglobulin A nephropathy (IgAN), though the activating mechanisms are unknown. This study focused on the gene expression of CD46 and CD55, two key molecules for regulating C3 convertase activity of lectin and alternative complement pathways at a cellular level.
METHODS: The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. Patients had a previous median follow-up of 6.4 (interquartile range 2.8-10.7) years and were divided into progressors and non-progressors according to the median value of their velocity of loss of renal function per year (-0.41 mL/min/1.73 m2/year).
RESULTS: CD46 and CD55 messenger RNA (mRNA) expression in WBCs was not correlated with eGFR values or proteinuria at sampling. CD46 mRNA was significantly correlated with eGFR decline rate as a continuous outcome variable (P = 0.014). A significant difference was found in CD46 gene expression between progressors and non-progressors (P = 0.013). CD46 and CD55 mRNA levels were significantly correlated (P < 0.01), although no difference between progressors and non-progressors was found for CD55 mRNA values. The prediction of progression was increased when CD46 and CD55 mRNA expressions were added to clinical data at renal biopsy (eGFR, proteinuria and mean arterial blood pressure) and Oxford MEST-C (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, presence of any crescents) score.
CONCLUSIONS: Patients with progressive IgAN showed lower expression of mRNA encoding for the complement inhibitory protein CD46, which may implicate a defective regulation of C3 convertase with uncontrolled complement activation.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  CD46; CD55; IgA nephropathy; biomarkers; complement

Mesh:

Substances:

Year:  2019        PMID: 29635535     DOI: 10.1093/ndt/gfy064

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies.

Authors:  Dita Maixnerova; Delphine El Mehdi; Dana V Rizk; Hong Zhang; Vladimir Tesar
Journal:  J Clin Med       Date:  2022-05-16       Impact factor: 4.964

2.  Expression levels of complement regulatory proteins (CD35, CD55 and CD59) on peripheral blood cells of patients with chronic kidney disease.

Authors:  Dalia Mahmoud Eldewi; Alshaymaa M Alhabibi; Hanaa Mohammed Eid El Sayed; Sammar Ahmed Kasim Mahmoud; Sanaa Mohammed El Sadek; Rasha Mahmoud Gouda; Mohammed Abd El Malik Hassan; Amal H Ibrahim; Naglaa F Abd El Haliem
Journal:  Int J Gen Med       Date:  2019-09-16

Review 3.  Emerging Modes of Treatment of IgA Nephropathy.

Authors:  Dita Maixnerova; Vladimir Tesar
Journal:  Int J Mol Sci       Date:  2020-11-28       Impact factor: 5.923

4.  C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.

Authors:  Annette Bruchfeld; Hasan Magin; Patrick Nachman; Samir Parikh; Richard Lafayette; Antonia Potarca; Shichang Miao; Pirow Bekker
Journal:  Clin Kidney J       Date:  2022-01-24

5.  Intrarenal Complement System Transcripts in Chronic Antibody-Mediated Rejection and Recurrent IgA Nephropathy in Kidney Transplantation.

Authors:  Marek Cernoch; Petra Hruba; Marek Kollar; Petra Mrazova; Lucia Stranavova; Alena Lodererova; Eva Honsova; Ondrej Viklicky
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.